Enfortumab Progresses As US Accelerated Approval Eyed In Urothelial Cancer
Executive Summary
Astellas and Seattle Genetics now expect key top-line data on their antibody-drug conjugate in urothelial cancer in the first half of next year, as pivotal trials in support of a planned US accelerated approval progress.
You may also be interested in...
ECHELON-2 Ushers In Another New Adcetris Indication For Seattle Genetics
The combination of Adcetris with chemotherapy improved progression-free and overall survival in peripheral T-cell lymphoma. Filing is expected soon, and approval will help the product reach blockbuster status.
Keytruda's Broad Confirmatory Trials Suggest Evolution Of US FDA’s Accelerated Approval Model
FDA’s most recent accelerated approvals for Merck’s Keytruda call for confirmatory trials in a broader patient population than the approved indications, in the latest example of FDA’s growing comfort with multi-purpose confirmatory trials in the PD-1/PD-L1 inhibitor space.
Breakthrough Status Arrives Late In Development Of Yervoy+Opdivo, Enfortumab Vedotin And Pedmark
US FDA's latest BTD awards go to Seattle Genetics and Astellas' antibody-drug conjugate for immunotherapy-experienced urothelial cancer, Fennec's supportive care product to reduce cisplatin ototoxicity in pediatric cancer patients, and Bristol's double immunotherapy combo in MSI-H colorectal cancer.